Biocon Biologics Ltd., a leading global biosimilars organization, has been named an Asia IP Elite for 2025 by Intellectual Asset Management (IAM). This prestigious recognition, presented at the IPBC Asia conference in Tokyo in November 2025, identifies regional leaders who demonstrate excellence in intellectual property (IP) value creation.

Since first appearing on the list in 2016 as the only Indian pharmaceutical company to be featured, Biocon and Biocon Biologics have maintained their position for nine consecutive years.

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, stated that the recognition "reflects our sustained commitment to innovation and strong intellectual property strategy," further solidifying the company's role in providing affordable, high-quality therapies worldwide.